As of January 23, 2025, Lucid Diagnostics (LUCD) has a market cap of $48.940 million USD. According to our data, Lucid Diagnostics is ranked No.8168 in global market value.
Year | Market Cap | %Change |
---|---|---|
Jan 23, 2025 | $48.94 M |
0.70%
|
Dec 31, 2024 | $48.60 M |
-41.91%
|
Dec 29, 2023 | $83.67 M |
3.68%
|
Dec 30, 2022 | $80.71 M |
-74.67%
|
Dec 31, 2021 | $0.32 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
Exact Sciences
EXAS
|
$10.14 B |
0.000 M
|
USA
|
Guardant Health
GH
|
$5.83 B |
0.000 M
|
USA
|
Natera
NTRA
|
$22.70 B |
-0.001 M
|
USA
|
Fulgent Genetics
FLGT
|
$0.52 B |
-0.000 M
|
USA
|
NeoGenomics
NEO
|
$1.86 B |
0.000 M
|
USA
|
Adaptive Biotechnologies
ADPT
|
$1.18 B |
0.000 M
|
USA
|
Personalis
PSNL
|
$0.47 B |
0.000 M
|
USA
|
Veracyte
VCYT
|
$3.34 B |
-0.000 M
|
USA
|
Myriad Genetics
MYGN
|
$1.12 B |
-0.000 M
|
USA
|
QuidelOrtho
QDEL
|
$2.99 B |
-0.000 M
|
USA
|
Hologic
HOLX
|
$16.07 B |
-0.000 M
|
USA
|
Illumina
ILMN
|
$22.26 B |
0.000 M
|
USA
|
Market Cap | = | LUCD Stock Price | * | LUCD Shares Outstanding |
= | $0.82 | * | 59.34 M | |
= | $48.94 M |